Mineralocorticoid receptor-mediated vascular insulin resistance: An early contributor to diabetes-related vascular disease?

Diabetes

Volumn 62, Issue 2, 2013, Pages 313-319

  Bender, Shawn B ^a,b   McGraw, Adam P ^c   Jaffe, Iris Z ^c   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HEART FAILURE; HUMAN; INSULIN RESISTANCE; NONHUMAN; OBESITY; OVERNUTRITION; PRIORITY JOURNAL; RENIN ANGIOTENSIN DISORDER; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ALDOSTERONE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OVERWEIGHT; RATS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84873027749     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0905     Document Type: Review

References (50)

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248
2. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012;33:191-202
3. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012;350:256-265
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
5. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
6. Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
7. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in post-myocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008;10:492-497
8. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515-2522
9. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-2514
10. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007;92:2552-2558
11. Caprio M, Newfell BG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102:1359-1367
12. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96:643-650
13. Newfell BG, Iyer LK, Mohammad NN, et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arterioscler Thromb Vasc Biol 2011;31:1871-1880
14. McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012;18: 1429-1433
15. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-1904
16. Sowers Jr. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597-H1602
17. Bender SB, Klabunde RE. Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and alpha1-adrenoceptor-mediated vasoconstriction in Type 2 diabetes. Am J Physiol Heart Circ Physiol 2007; 293:H2281-H2288
18. Bender SB, Newcomer SC, Laughlin MH. Differential vulnerability of skeletal muscle feed arteries to dysfunction in insulin resistance: impact of fiber type and daily activity. Am J Physiol Heart Circ Physiol 2011;300: H1434-H1441
19. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in en-dothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294-307
20. Eringa EC, Stehouwer CDA, Roos MH, Westerhof N, Sipkema P. Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol Endocrinol Metab 2007;293:E1134-E1139
21. Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2006; 291:H1780-H1787
22. Katakam PV, Tulbert CD, Snipes JA, Erdös B, Miller AW, Busija DW. Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species. Am J Physiol Heart Circ Physiol 2005;288:H854-H860
23. Li R, Zhang H, Wang W, et al. Vascular insulin resistance in pre-hypertensive rats: role of PI3-kinase/Akt/eNOS signaling. Eur J Pharmacol 2010;628:140-147
24. Schulman IH, Zhou M-S, Jaimes EA, Raij L. Dissociation between metabolic and vascular insulin resistance in aging. Am J Physiol Heart Circ Physiol 2007;293:H853-H859
25. Perticone F, Sciacqua A, Scozzafava A, et al. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 2004;89: 3606-3609
26. Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 2008;57:3307-3314
27. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011;13:163-172
28. Feldman RD, Schmidt ND. Moderate dietary salt restriction increases vascular and systemic insulin resistance. Am J Hypertens 1999;12: 643-647
29. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010;95:1986-1990
30. Jeon JH, Kim KY, Kim JH, et al. A novel adipokine CTRP1 stimulates al-dosterone production. FASEB J 2008;22:1502-1511
31. Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007;50:750-755
32. Sherajee SJ, Fujita Y, Rafiq K, et al. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 2012;32:257-263
33. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez Jr. Angio-tensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009;302:128-139
34. Draznin B. Molecular mechanisms of insulin resistance: serine phosphor-ylation of insulin receptor substrate-1 and increased expression of p85a: the two sides of a coin. Diabetes 2006;55:2392-2397
35. Montezano AC, Callera GE, Yogi A, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008;28:1511-1518
36. Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol 2009;296:F1323-F1333
37. Cascella T, Radhakrishnan Y, Maile LA, et al. Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology 2010;151:5851-5864
38. Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and en-dothelial function. Curr Opin Investig Drugs 2008;9:963-969
39. Gogg S, Smith U, Jansson P-A. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes 2009;58:2238-2245
40. Deuchar GA, McLean D, Hadoke PWF, et al. 11b-hydroxysteroid de-hydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/-mice. Endocrinology 2011;152:236-246
41. Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006;26:917-921
42. Rask-Madsen C, Buonomo E, Li Q, et al. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2012;32:1124-1131
43. Galkina EV, Butcher M, Keller SR, et al. Accelerated atherosclerosis in Apoe-/-mice heterozygous for the insulin receptor and the insulin receptor substrate-1. Arterioscler Thromb Vasc Biol 2012;32:247-256
44. Hodroj W, Legedz L, Foudi N, et al. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol 2007;27:525-531
45. Ihara Y, Egashira K, Nakano K, et al. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol 2007;43: 455-464
46. Hirai H, Kanaya R, Maeda M, Qungfang D, Ina K, Hayashi T. The role of insulin growth factor on atherosclerosis and endothelial function: the effect on hyperlipidemia and aging. Life Sci 2011;88:425-431
47. Burchardt P, Gozdzicka-Jozefiak A, Zurawski J, et al. Are elevated levels of IGF-1 caused by coronary arteriesoclerosis?: Molecular and clinical analysis. Protein J 2010;29:538-544
48. Shai S-Y, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/-mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol 2010;30:1916-1924
49. von der Thüsen JH, Borensztajn KS, Moimas S, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am J Pathol 2011;178:924-934
50. Li G, Barrett EJ, Ko S-H, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology 2009;150: 3475-3482